Related Experiment Video
Updated: Aug 14, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Enzyme PTP-1B Inhibition Studies by Vanadium Metal Complexes: a Kinetic Approach
Ayub Shaik1, Vani Kondaparthy2, Alia Begum3
1Department of Chemistry, Osmania University, Hyderabad, Telangana, 500007, India. drayubsk@osmania.ac.in.
Abstract:
The medical field now needs more novel drugs to treat obesity and type-2 diabetes mellitus (T2D) than ever before. Obesity and T2D are both characterized by resistance to the hormones leptin and insulin. PTP-1B is a promising target for drug growth, as strong genetic, pharmacological, and biochemical evidence points to the possibility of treating diabetes and obesity by blocking the PTP-1B enzyme. Studies have also found that PTP-1B is overexpressed in patients with diabetes and obesity, suggesting that inhibiting PTP-1B may be a useful technique in their care. There are no clinically used PTP-1B inhibitors, despite the fact that numerous naturally occurring PTP-1B inhibitors have demonstrated great therapeutic promise. This is most likely due to their low activity or lack of selectivity. It is still important to look for more effective and focused PTP-1B inhibitors. A few organovanadium metal complexes were synthesized and characterized, and binding studies on vanadium complexes with PTP-B were also performed using fluorescence emission spectroscopy. Additionally, we theoretically (molecular modeling) and experimentally (enzyme kinetics) examined the PTP-1B inhibitory effects of these vanadium metal complexes and found that they have excellent PTP-1B inhibitory properties.
Insights
Novel organovanadium metal complexes show excellent PTP-1B inhibitory properties, offering a promising new avenue for developing drugs to treat obesity and type-2 diabetes mellitus (T2D). Further research is needed to explore their therapeutic potential.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Obesity and type-2 diabetes mellitus (T2D) are significant global health challenges, characterized by leptin and insulin resistance.
- Protein tyrosine phosphatase 1B (PTP-1B) is a key enzyme implicated in both obesity and T2D pathogenesis.
- Current therapeutic strategies are insufficient, necessitating the development of novel drugs targeting PTP-1B.
Purpose of the Study:
- To synthesize and characterize novel organovanadium metal complexes.
- To investigate the PTP-1B inhibitory potential of these vanadium complexes.
- To explore the therapeutic implications of PTP-1B inhibition for obesity and T2D.
Main Methods:
- Synthesis and characterization of organovanadium metal complexes.
- Fluorescence emission spectroscopy for binding studies with PTP-1B.
- Molecular modeling and enzyme kinetics for evaluating PTP-1B inhibitory effects.
Main Results:
- Organovanadium metal complexes were successfully synthesized and characterized.
- Binding studies confirmed interactions between vanadium complexes and PTP-1B.
- Both theoretical and experimental analyses demonstrated excellent PTP-1B inhibitory properties of the vanadium complexes.
Conclusions:
- Organovanadium metal complexes exhibit potent PTP-1B inhibitory activity.
- These complexes represent a promising class of compounds for the development of new anti-obesity and anti-diabetic drugs.
- Further investigation into selectivity and in vivo efficacy is warranted.
Related Concept Videos
Introduction to Enzyme Kinetics
The experimenter can then plot the initial reaction rate or velocity (Vo) of a given trial against the substrate concentration ([S]) to obtain a graph of the reaction properties. For many enzymatic reactions involving a...
Enzyme Kinetics
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...
Enzyme Inhibition
Valence Bond Theory
ATP Synthase: Mechanism
Van der Waals Interactions

